Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.32 |
| ▸ | JUN | P05412 | 7/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.32 |
| ▸ | RELA | Q04206 | 7/20 | 0.32 |
| ▸ | FOS | P01100 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8891742 | 0.68 | CA12 (0.50) | — | |
| SCHEMBL25255933 | 0.67 | ALDH1A1 (0.44) | — | |
| SCHEMBL10007017 | 0.66 | XPO1 (0.38) | XPO1JUNNFKB1NFKB2RELA | |
| SCHEMBL12583854 | 0.64 | CA12 (0.41) | JUNNFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL5808464 | 0.64 | NPC1 (0.48) | XPO1JUNNFKB1NFKB2RELA | |
| SCHEMBL19157252 | 0.64 | — | — | |
| SCHEMBL18897410 | 0.64 | — | — | |
| SCHEMBL4256829 | 0.63 | KDM4E (0.46) | — | |
| SCHEMBL4395914 | 0.62 | MGLL (0.33) | XPO1 | |
| SCHEMBL23811165 | 0.61 | GSK3A (0.37) | JUNNFKB1NFKB2RELAFOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3154997-B1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3313522-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313524-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3310440-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-25 | — | — | EP | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| EP-3233127-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015096982-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-02 | — | — | WO | disclosed |
| EP-2790731-A2 | FGFR-BINDER-ACTIVE AGENT CONJUGATES | Seattle Genetics, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| EP-2699268-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | Seattle Genetics, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2013087716-A2 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143499-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143497-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | XPO1 3153/4885JUN 3795/4885NFKB1 3463/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | XPO1 1356/4885JUN 3655/4885NFKB1 2551/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | XPO1 1118/4885JUN 2829/4885NFKB1 968/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | XPO1 3153/4885JUN 3795/4885NFKB1 3463/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | XPO1 1118/4885JUN 2829/4885NFKB1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.